# **EnteraFlux**

**Know Before It Hurts.**

EnteraFlux is an AI-powered metabolic safety and research intelligence platform designed to support individuals using GLP-1 metabolic medications (Ozempic, Wegovy, Mounjaro, Zepbound, etc.) by predicting adverse tolerance events, guiding behavioral interventions, detecting counterfeit drug threats, and accelerating pharmacovigilance research.

---

## **Mission Statement**

> **To make metabolic therapies safer, more tolerable, and more accessible by unlocking the physiological signals that predict treatment response.**

---

## **What EnteraFlux Does**

EnteraFlux provides a unified safety & intelligence layer for GLP-1 and incretin-based therapeutics through:

### **1. Predictive Tolerance Monitoring**

Uses wearable biometrics (HRV, RHR, sleep disruption, stress markers) to predict:

* nausea risk
* GI intolerance
* adherence failure
* metabolic stress

### **2. Adaptive Behavioral Guidance**

Provides real-time recommendations for:

* meal timing & composition
* hydration & electrolytes
* workout postponement
* anti-nausea strategies

### **3. Severe Risk Escalation**

If severe psychiatric risk is inferred (e.g., suicidality), system can:

* alert emergency contact (future module)

### **4. Counterfeit Drug Intelligence**

Analyzes sellers across:

* websites
* social groups
* marketplaces

to detect labeling inconsistencies and fraudulent supply chain risk.

### **5. Pharmacovigilance Intelligence**

Extracts emerging side-effect patterns from:

* Twitter/X
* Reddit
* clinical trial publications

and produces structured reports for:

* manufacturers
* CROs
* regulatory bodies (FDA, EMA, CDSCO etc.)

### **6. Research & Clinical Trial Enablement**

Provides future support for:

* cohort matching
* FHIR-compliant data exchange
* e-consent workflows

---

## **Brand Positioning Pillars**

1. **Predictive Safety** â€” We don't wait for side effects. We predict them.
2. **Physiological Intelligence** â€” The body produces signals. EnteraFlux interprets them.
3. **Evidence, Not Guesswork** â€” Decisions rooted in biomarkers, not anecdotes.
4. **Guidance Over Restriction** â€” We guide behavior. We never shame it.
5. **Partnership with Medicine** â€” We extend clinicians, not replace them.
6. **Regulatory Alignment** â€” Built for research. Built for safety. Built for validation.

---

## **Repository Structure**

For now, this repository includes the two primary user-facing interfaces:

```
/user_app       â†’ Mobile application (React Native) for patient interaction
/web_app        â†’ Marketing + informational web application for EnteraFlux
```

### **Under Development Modules (Not Yet Pushed)**

The following components are currently under active development and will be added to the repository as they mature:

```
/core_anomaly_engine            â†’ Wearable biomarker anomaly detection
/coaching_engine                â†’ Adaptive behavioral guidance system
/counterfeit_intelligence       â†’ CV + NLP module for counterfeit drug analysis
/pharmacovigilance_intelligence â†’ Social + trial data side-effect signal detector
/research_api                   â†’ FHIR + CRO interoperability services
/emergency_escalation           â†’ Psychiatric/severe risk alerting pipeline
/data_lake                      â†’ Encrypted physiological + symptom data layer
/model_serving                  â†’ AI inference services
```

---

## **Current Development Status**

EnteraFlux is currently in **active development**.

Badges & status declarations:

* **Platform Under Development**
* **Not a Medical Device**
* **Not for Clinical Use Yet**
* **Research-Only Phase**
* **Pending Validation**
* **Beta Access Opening Soon**

---

## **Primary Target Users**

EnteraFlux serves multiple stakeholders:

### **Patients**

Predictive tolerance + guided behavioral safety

### **Manufacturers / Pharma / Biotech**

Post-market surveillance + cohort pipelines

### **Clinical Researchers / CROs**

Real-world evidence + trial recruitment

### **Regulatory Bodies**

Safety signal intelligence + counterfeit detection

---

## ðŸ **Roadmap (High-Level)**

| Phase                        | Status      |
| ---------------------------- | ----------- |
| Alpha Biomarker Models       | In Progress |
| Web App + Brand              | In Progress |
| User Mobile App              | In Progress |
| Counterfeit Intelligence     | Planned     |
| Pharmacovigilance Engine     | Planned     |
| Trial Recruitment Engine     | Planned     |
| Emergency Contact Escalation | Planned     |
| Regulatory Validation        | Future      |
| Commercial Deployment        | Future      |

A more detailed roadmap will be published as internal modules mature.

---

## **Tech Stack Overview (Current)**

| Layer                   | Tech                                     |
| ----------------------- | ---------------------------------------- |
| Mobile App              | React Native + TS                        |
| Web App                 | Next.js/React + TS + Tailwind            |
| Models (Future)         | PyTorch + Scikit-learn + HF Transformers |
| Data Interface (Future) | FHIR + HealthKit + Google Fit            |
| Backend (Future)        | FastAPI + Node microservices             |
| Storage (Future)        | PostgreSQL + Redis                       |
| Inference (Future)      | Model Serving Pipeline (TBD)             |

---

## **Contact**

For collaboration, research interest, or pilot partnerships:

> **[contact.enteraflux@gmail.com](mailto:contact.enteraflux@gmail.com)** (placeholder until domain setup)

---

## **Legal & Compliance**

EnteraFlux is currently:

* **Not a Medical Device**
* **Not FDA/EMA/MHRA approved**
* **Not for clinical or diagnostic use**
* **For research & development only**

Future regulatory pathways will be evaluated for:

* FDA SaMD clearance
* HIPAA compliance
* GDPR compliance
* ISO 13485 / 14971 (if applicable)

---
